mpact is the name of the p3 trial that showed adding abraxane to gemcitabine increased median survival over gemcitabine by itself. It’s published. Yes abraxane was approved in pancreatic cancer based on mpact.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-10
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.19M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 150000 | 6.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.6¢ | 150000 | 1 |
View Market Depth
| Last trade - 16.12pm 19/06/2024 (20 minute delay) ? |
| ATX (ASX) Chart |
Day chart unavailable